A new era for chagas disease drug discovery?

Progress in Medicinal Chemistry

Volumn 54, Issue , 2015, Pages 185-230

  Keenan, Martine ^a   Chaplin, Jason H ^a  

^a Murdoch University Campus   (Australia)

Author keywords

14 demethylase; Benznidazole; Chagas disease; Clinical trial; CYP51; Drug re purposing; Neglected tropical disease; Phenotypic screening; Screening cascade; Sterol; Trypanosoma cruzi

Indexed keywords

BENZNIDAZOLE; HETEROCYCLIC COMPOUND; NITRO DERIVATIVE; STEROL 14ALPHA DEMETHYLASE INHIBITOR; NITROIMIDAZOLE DERIVATIVE;

ARTICLE; CHAGAS DISEASE; DRUG SCREENING; DRUG TARGETING; HOST PARASITE INTERACTION; HUMAN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; STEROL SYNTHESIS; TRYPANOSOMA CRUZI; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT;

14-ALPHA DEMETHYLASE INHIBITORS; CHAGAS DISEASE; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HUMANS; NITROIMIDAZOLES;

EID: 84923092621     PISSN: 00796468     EISSN: 18757863     Source Type: Book Series    
DOI: 10.1016/bs.pmch.2014.12.001     Document Type: Chapter

References (159)

1. World Health Organisation FSN 340 Chagas disease (American trypanosomiasis) 2014 Médecine et maladies infectieuses
2. S.P. Montgomery, M.C. Starr, P.T. Cantey, M.S. Edwards, and S.K. Meymandi Neglected parasitic infections in the United States: Chagas disease Am J Trop Med Hyg 90 5 2014 814 818
3. M. Navarro, B. Navaza, A. Guionnet, and R. López-Vélez Chagas disease in Spain: need for further public health measures PLoS Negl Trop Dis 6 12 2012 e1962
4. J.A. Perez-Molina, C. Poveda, A. Martinez-Perez, F. Guhl, B. Monge-Maillo, and M. Fresno Distribution of Trypanosoma cruzi discrete typing units in Bolivian migrants in Spain Infect Genet Evol 21 2014 440 442
5. Y. Jackson, A. Pinto, and S. Pett Chagas disease in Australia and New Zealand: risks and needs for public health interventions Trop Med Int Heal 19 2 2014 212 218
6. I. Molina, J. Gómez i Prat, F. Salvador, B. Treviño, E. Sulleiro, and N. Serre Randomized trial of posaconazole and benznidazole for chronic Chagas' disease N Engl J Med 370 20 2014 1899 1908
7. I. Ribeiro, T. Faustino, and J. Gascon E1224 - results of proof of concept clinical trial in patients with chronic indeterminate Chagas disease Abstract presented at ASTMH 62nd Annual Meeting 2013
8. G.I. Lepesheva, and M.R. Waterman Structural basis for conservation in the CYP51 family Biochim Biophys Acta 1814 1 2011 88 93
9. G.I. Lepesheva, R.D. Ott, T.Y. Hargrove, Y.Y. Kleshchenko, W.D. Nes, and G.C. Hill Sterol 14α-demethylase as a potential target for antitrypanosomal therapy: enzyme inhibition and parasite cell growth Chem Biol 14 11 2007 1283 1293
10. B.S. Hall, and S.R. Wilkinson Activation of benznidazole by trypanosomal type I nitroreductases results in glyoxal formation Antimicrob Agents Chemother 56 1 2012 115 123
11. A. Trochine, D.J. Creek, P. Faral-Tello, M.P. Barrett, and C. Robello Benznidazole biotransformation and multiple targets in Trypanosoma cruzi revealed by metabolomics PLoS Negl Trop Dis 8 5 2014 e2844
12. M.-J. Pinazo, J. Muñoz, E. Posada, P. López-Chejade, M. Gállego, and E. Ayala Tolerance of benznidazole in treatment of Chagas' disease in adults Antimicrob Agents Chemother 54 11 2010 4896 4899
13. J.A. Castro, M.M. de Mecca, and L.C. Bartel Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis) Hum Exp Toxicol 25 8 2006 471 479
14. A.F. Stepan, D.P. Walker, J. Bauman, D.A. Price, T.A. Baillie, and A.S. Kalgutkar Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States Chem Res Toxicol 24 9 2011 1345 1410
15. C. Bern Antitrypanosomal therapy for chronic Chagas' disease N Engl J Med 364 26 2011 2527 2534
16. M.-J. Pinazo, L. Guerrero, E. Posada, E. Rodríguez, D. Soy, and J. Gascon Benznidazole-related adverse drug reactions and their relationship to serum drug concentrations in patients with chronic Chagas disease Antimicrob Agents Chemother 57 1 2013 390 395
17. A. Haberland, S.G.M. Saravia, G. Wallukat, R. Ziebig, and I. Schimke Chronic Chagas disease: from basics to laboratory medicine Clin Chem Lab Med 51 2 2013 271 294
18. A. Rassi, and J. Marcondes de Rezende American trypanosomiasis (Chagas disease) Infect Dis Clin North Am 26 2 2012 275 291
19. P.M. Matta Guedes, F.R.S. Gutierrez, M.S.L. Nascimento, M.A. Do-Valle-Matta, and J.S. Silva Antiparasitical chemotherapy in Chagas' disease cardiomyopathy: current evidence Trop Med Int Health 17 9 2012 1057 1065
20. J. Altcheh, G. Moscatelli, S. Moroni, F. Garcia-Bournissen, and H. Freilij Adverse events after the use of benznidazole in infants and children with Chagas disease Pediatrics 127 1 2011 e212 e218
21. Y. Moolani, G. Bukhman, and P.J. Hotez Neglected tropical diseases as hidden causes of cardiovascular disease PLoS Negl Trop Dis 6 6 2012 e1499
22. A.M. Hasslocher-Moreno, P.E.A.A. do Brasil, A.S. de Sousa, S.S. Xavier, M.C. Chambela, and G.M. Sperandio da Silva Safety of benznidazole use in the treatment of chronic Chagas' disease J Antimicrob Chemother 67 5 2012 1261 1266
23. J.R. Coura, and J. Borges-Pereira Chronic phase of Chagas disease: why should it be treated? A comprehensive review Mem Inst Oswaldo Cruz 106 6 2011 641 645
24. G.I. Lepesheva, F. Villalta, and M.R. Waterman Targeting Trypanosoma cruzi sterol 14α-demethylase (CYP51) Adv Parasitol 75 2011 65 87
25. G.I. Lepesheva, and M.R. Waterman Sterol 14alpha-demethylase (CYP51) as a therapeutic target for human trypanosomiasis and leishmaniasis Curr Top Med Chem 11 16 2012 2060 2071
26. J.A. Urbina Ergosterol biosynthesis and drug development for Chagas disease Mem Inst Oswaldo Cruz 104 Suppl. (May) 2009 311 318
27. J.A. Urbina Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches Acta Trop 115 1-2 2010 55 68 Elsevier B.V
28. J.A. Urbina, G. Payares, J. Molina, C. Sanoja, a. Liendo, and K. Lazardi Cure of short- and long-term experimental Chagas' disease using D0870 Science 273 5277 1996 969 971
29. J.A. Urbina, K. Lazardi, T. Aguirre, M.M. Piras, and R. Piras Antiproliferative effects and mechanism of action of ICI 195,739, a novel bis-triazole derivative, on epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi Antimicrob Agents Chemother 35 4 1991 730 735
30. K. Lazardi, J.A. Urbina, and W. de Souza Ultrastructural alterations induced by ICI 195,739, a bis-triazole derivative with strong antiproliferative action against Trypanosoma (Schizotrypanum) cruzi Antimicrob Agents Chemother 35 4 1991 736 740
31. J. Molina, Z. Brener, A.J. Romanha, and J.A. Urbina In vivo activity of the bis-triazole D0870 against drug-susceptible and drug-resistant strains of the protozoan parasite Trypanosoma cruzi J Antimicrob Chemother 46 2000 137 140
32. K.J. Williams, and D.W. Denning Termination of development of D0870 J Antimicrob Chemother 47 5 2001 720 721
33. J.A. Urbina, G. Payares, C. Sanoja, J. Molina, R. Lira, and Z. Brener Parasitological cure of acute and chronic experimental Chagas disease using the long-acting experimental triazole TAK-187. Activity against drug-resistant Trypanosoma cruzi strains Int J Antimicrob Agents 21 2003 39 48
34. M. Corrales, R. Cardozo, M.A. Segura, J.A. Urbina, M.A. Basombrío, and M.A. BasombrI Comparative efficacies of TAK-187, a long-lasting ergosterol biosynthesis inhibitor, and benznidazole in preventing cardiac damage in a Murine Model of Chagas' Disease Antimicrob Agents Chemother 49 4 2005 1556 1560
35. J.A. Urbina, G. Payares, L.M. Contreras, C. Sanoja, J. Molina, and M. Piras Antiproliferative effects and mechanism of action of SCH 56592 against Trypanosoma (schizotrypanum) cruzi: in vitro and in vivo studies Antimicrob Agents Chemother 42 7 1998 1771 1777
36. V. Nagappan, and S. Deresinski Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent Clin Infect Dis 45 12 2007 1610 1617
37. M.-J. Pinazo, G. Espinosa, M. Gállego, P.L. López-Chejade, J.A. Urbina, and J. Gascón Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus Am J Trop Med Hyg 82 4 2010 583 587
38. Clinical trial for the treatment of chronic Chagas disease with posaconazole and benznidazole (CHAGASAZOL). www.clinicaltrials.gov # NCT01162967.
39. A study of the use of oral posaconazole (POS) in the treatment of asymptomatic chronic Chagas disease. www.clinicaltrials.gov # NCT01377480.
40. Proof-of-concept study of E1224 to treat adult patients with Chagas disease. www.clinicaltrials.gov # NCT01489228.
41. J.A. Urbina, G. Payares, C. Sanoja, and R. Lira In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease Int J Antimicrob Agents 21 2003 27 38
42. K. Hata, J. Kimura, H. Miki, T. Toyosawa, T. Nakamura, and K. Katsu In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum Antimicrob Agents Chemother 40 10 1996 2237 2242
43. L.D.F. Diniz, I.S. Caldas, P.M.D.M. Guedes, G. Crepalde, M. de Lana, and C.M. Carneiro Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi Antimicrob Agents Chemother 54 7 2010 2979 2986
44. R. Nagarkatti, F.F. de Araujo, C. Gupta, and A. Debrabant Aptamer based, non-PCR, non-serological detection of Chagas disease biomarkers in Trypanosoma cruzi infected mice PLoS Negl Trop Dis 8 1 2014 e2650
45. C.B. Moraes, Ma. Giardini, H. Kim, C.H. Franco, A.M. Araujo-Junior, and S. Schenkman Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development Sci Rep 4 2014 4703
46. B. Zingales, M.a. Miles, D.a. Campbell, M. Tibayrenc, A.M. Macedo, and M.M.G. Teixeira The revised Trypanosoma cruzi subspecific nomenclature: rationale, epidemiological relevance and research applications Infect Genet Evol 12 2 2012 240 253 Elsevier B.V
47. H.M.S. Valadares, J.R. Pimenta, M. Segatto, V.M. Veloso, M.L. Gomes, and E. Chiari Unequivocal identification of subpopulations in putative multiclonal Trypanosoma cruzi strains by FACs single cell sorting and genotyping PLoS Negl Trop Dis 6 7 2012 e1722
48. I. Ribeiro, A.-M. Sevcsik, F. Alves, G. Diap, R. Don, and M.O. Harhay New, improved treatments for Chagas disease: from the R&D pipeline to the patients PLoS Negl Trop Dis 3 7 2009 e484
49. M.L. Sykes, and V.M. Avery Approaches to protozoan drug discovery: phenotypic screening J Med Chem 56 20 2013 7727 7740
50. J.C. Engel, K.K.H. Ang, S. Chen, M.R. Arkin, J.H. McKerrow, and P.S. Doyle Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease Antimicrob Agents Chemother 54 8 2010 3326 3334
51. S. Moon, J.L. Siqueira-Neto, C.B. Moraes, G. Yang, M. Kang, and L.H. Freitas-Junior An image-based algorithm for precise and accurate high throughput assessment of drug activity against the human parasite Trypanosoma cruzi PLoS One 9 2 2014 e87188
52. F.S. Buckner Experimental chemotherapy and approaches to drug discovery for Trypanosoma cruzi infection Adv Parasitol 75 2011 89 119
53. J. Molina, O. Martins-filho, Z. Brener, J. Romanha, D. Loebenberg, and J.A. Urbina Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts Antimicrob Agents Chemother 44 1 2000 150 155
54. L.D.F. Diniz, J.A. Urbina, I.M. de Andrade, A.L. Mazzeti, T.A.F. Martins, and I.S. Caldas Benznidazole and posaconazole in experimental Chagas disease: positive interaction in concomitant and sequential treatments PLoS Negl Trop Dis 7 8 2013 e2367
55. J.M. Bustamante, L.M. Bixby, and R.L. Tarleton Drug-induced cure drives conversion to a stable and protective CD8 + T central memory response in chronic Chagas disease Nat Med 14 5 2008 542 550
56. J.M. Bustamante, J.M. Craft, B.D. Crowe, S.A. Ketchie, and R.L. Tarleton New, combined, and reduced dosing treatment protocols cure Trypanosoma cruzi infection in mice J Infect Dis 209 1 2014 150 162
57. S. Cencig, N. Coltel, C. Truyens, and Y. Carlier Evaluation of benznidazole treatment combined with nifurtimox, posaconazole or Am Bisome® in mice infected with Trypanosoma cruzi strains Int J Antimicrob Agents 40 6 2012 527 532 Elsevier B.V
58. M.C. Taylor, and J.M. Kelly Optimizing bioluminescence imaging to study protozoan parasite infections Trends Parasitol 30 4 2014 161 162 Elsevier Ltd
59. M. Hutchens, and G.D. Luker Applications of bioluminescence imaging to the study of infectious diseases Cell Microbiol 9 10 2007 2315 2322
60. T. Lang, S. Goyard, M. Lebastard, and G. Milon Bioluminescent Leishmania expressing luciferase for rapid and high throughput screening of drugs acting on amastigote-harbouring macrophages and for quantitative real-time monitoring of parasitism features in living mice Cell Microbiol 7 3 2005 383 392
61. E. Myburgh, J.A. Coles, R. Ritchie, P.G.E. Kennedy, A.P. McLatchie, and J. Rodgers In vivo imaging of trypanosome-brain interactions and development of a rapid screening test for drugs against CNS stage trypanosomiasis PLoS Negl Trop Dis 7 8 2013 e2384
62. A.M.C. Canavaci, J.M. Bustamante, A.M. Padilla, C.M. Perez Brandan, L.J. Simpson, and D. Xu In vitro and in vivo high-throughput assays for the testing of anti-Trypanosoma cruzi compounds PLoS Negl Trop Dis 4 7 2010 e740
63. K.V. Hyland, S.H. Asfaw, C.L. Olson, M.D. Daniels, and D.M. Engman Bioluminescent imaging of Trypanosoma cruzi infection Int J Parasitol 38 12 2008 1391 1400
64. B.R. Branchini, D.M. Ablamsky, A.L. Davis, T.L. Southworth, B. Butler, and F. Fan Red-emitting luciferases for bioluminescence reporter and imaging applications Anal Biochem 396 2 2010 290 297 Elsevier Inc
65. M.D. Lewis, A. Fortes Francisco, M.C. Taylor, H. Burrell-Saward, A.P. McLatchie, and M.A. Miles Bioluminescence imaging of chronic Trypanosoma cruzi infections reveals tissue-specific parasite dynamics and heart disease in the absence of locally persistent infection Cell Microbiol 16 9 2014 1285 1300
66. C.J. Perez, A.J. Lymbery, and R.C.A. Thompson Chagas disease: the challenge of polyparasitism? Trends Parasitol 30 4 2014 176 182 Elsevier Ltd
67. C. Aquilino, M.L. Gonzalez Rubio, E.M. Seco, L. Escudero, L. Corvo, and M. Soto Differential trypanocidal activity of novel macrolide antibiotics; correlation to genetic lineage PLoS One 7 7 2012 e40901
68. F. Buckner, K. Yokoyama, J. Lockman, K. Aikenhead, J. Ohkanda, and M. Sadilek A class of sterol 14-demethylase inhibitors as anti-Trypanosoma cruzi agents Proc Natl Acad Sci USA 100 25 2003 15149 15153
69. J.M. Kraus, H.B. Tatipaka, S.A. McGuffin, N.K. Chennamaneni, M. Karimi, and J. Arif Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery J Med Chem 53 10 2010 3887 3898
70. F.S. Buckner, M.T. Bahia, P.K. Suryadevara, K.L. White, D.M. Shackleford, and N.K. Chennamaneni Pharmacological characterization, structural studies, and in vivo activities of anti-Chagas disease lead compounds derived from tipifarnib Antimicrob Agents Chemother 56 9 2012 4914 4921
71. S.S. Gunatilleke, C.M. Calvet, J.B. Johnston, C.-K. Chen, G. Erenburg, and J. Gut Diverse inhibitor chemotypes targeting Trypanosoma cruzi CYP51 PLoS Negl Trop Dis 6 7 2012 e1736
72. G.I. Lepesheva, T.Y. Hargrove, S. Anderson, Y. Kleshchenko, V. Furtak, and Z. Wawrzak Structural insights into inhibition of sterol 14alpha-demethylase in the human pathogen Trypanosoma cruzi J Biol Chem 285 33 2010 25582 25590
73. C.-K. Chen, S.S.F. Leung, C. Guilbert, M.P. Jacobson, J.H. McKerrow, and L.M. Podust Structural characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei bound to the antifungal drugs posaconazole and fluconazole PLoS Negl Trop Dis 4 4 2010 e651
74. T.Y. Hargrove, K. Kim, M. de Nazaré Correia Soeiro, C.F. da Silva, D. da Gama Jaen Batista, and M.M. Batista CYP51 structures and structure-based development of novel, pathogen-specific inhibitory scaffolds Int J Parasitol Drugs Drug Resist 2 June 2012 178 186 Australian Society for Parasitology
75. F. Villalta, M.C. Dobish, P.N. Nde, Y.Y. Kleshchenko, T.Y. Hargrove, and Ca. Johnson VNI cures acute and chronic experimental Chagas disease J Infect Dis 208 3 2013 504 511
76. M.D.N.C. Soeiro, E.M. de Souza, C.F. da Silva, D.D.G.J. Batista, M.M. Batista, and B.P. Pavão In vitro and in vivo studies of the antiparasitic activity of sterol 14α-demethylase (CYP51) inhibitor VNI against drug-resistant strains of Trypanosoma cruzi Antimicrob Agents Chemother 57 9 2013 4151 4163
77. M. Keenan, M.J. Abbott, P.W. Alexander, T. Armstrong, W.M. Best, and B. Berven Analogues of fenarimol are potent inhibitors of Trypanosoma cruzi and are efficacious in a murine model of Chagas disease J Med Chem 55 9 2012 4189 4204
78. M. Keenan, P.W. Alexander, H. Diao, W.M. Best, A. Khong, and M. Kerfoot Design, structure-activity relationship and in vivo efficacy of piperazine analogues of fenarimol as inhibitors of Trypanosoma cruzi Bioorg Med Chem 21 7 2013 1756 1763
79. M. Keenan, J.H. Chaplin, P.W. Alexander, M.J. Abbott, W.M. Best, and A. Khong Two analogues of fenarimol show curative activity in an experimental model of Chagas disease J Med Chem 56 24 2013 10158 10170
80. T.Y. Hargrove, Z. Wawrzak, P.W. Alexander, J.H. Chaplin, M. Keenan, and S.A. Charman Complexes of Trypanosoma cruzi sterol 14α-demethylase (CYP51) with two pyridine-based drug candidates for Chagas disease: structural basis for pathogen selectivity J Biol Chem 288 44 2013 31602 31615
81. M. Keenan, M.J. Abbott, H. Diao, Z. Wang, W.M. Best, and S.K. Keatley Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi Future Med Chem 5 15 2013 1733 1752
82. S. Dandapani, A.R. Germain, I. Jewett, S. le Quement, J.-C. Marie, and G. Muncipinto Diversity-oriented synthesis yields a new drug lead for treatment of Chagas disease ACS Med Chem Lett 5 2 2014 149 153
83. S. Nwaka, D. Besson, B. Ramirez, L. Maes, A. Matheeussen, and Q. Bickle Integrated dataset of screening hits against multiple neglected disease pathogens PLoS Negl Trop Dis 5 12 2011 e1412
84. R.S. Upadhayaya, S.S. Dixit, A. Földesi, and J. Chattopadhyaya New antiprotozoal agents: their synthesis and biological evaluations Bioorg Med Chem Lett 23 9 2013 2750 2758 Elsevier Ltd
85. A.M. Sanz, F. Gómez-Contreras, P. Navarro, M. Sánchez-Moreno, S. Boutaleb-Charki, and J. Campuzano Efficient inhibition of iron superoxide dismutase and of Trypanosoma cruzi growth by benzo[g]phthalazine derivatives functionalized with one or two imidazole rings J Med Chem 51 6 2008 1962 1966
86. M. Sánchez-Moreno, A.M. Sanz, F. Gómez-Contreras, P. Navarro, C. Marín, and I. Ramírez-Macias In vivo trypanosomicidal activity of imidazole- or pyrazole-based benzo[g]phthalazine derivatives against acute and chronic phases of Chagas disease J Med Chem 54 4 2011 970 979
87. M. Sánchez-Moreno, F. Gómez-Contreras, P. Navarro, C. Marín, F. Olmo, and M.J.R. Yunta Phthalazine derivatives containing imidazole rings behave as Fe-SOD inhibitors and show remarkable anti-T. cruzi activity in immunodeficient-mouse mode of infection J Med Chem 55 22 2012 9900 9913
88. M.C. Taylor, and J.M. Kelly Iron metabolism in trypanosomatids, and its crucial role in infection Parasitology 137 6 2010 899 917
89. A. Martinez, G. Peluffo, Aa. Petruk, M. Hugo, D. Piñeyro, and V. Demicheli Structural and molecular basis of the peroxynitrite-mediated nitration and inactivation of Trypanosoma cruzi iron-superoxide dismutases (Fe-SODs) A and B: disparate susceptibilities due to the repair of Tyr35 radical by Cys83 in Fe-SODB through intramolec J Biol Chem 289 18 2014 12760 12778
90. W. De Souza, and J.C.F. Rodrigues Sterol biosynthesis pathway as target for anti-trypanosomatid drugs Interdiscip Perspect Infect Dis 2009 2009 642502
91. N. Shang, Q. Li, T.-P. Ko, H.-C. Chan, J. Li, and Y. Zheng Squalene synthase as a target for Chagas disease therapeutics PLoS Pathog 10 5 2014 e1004114
92. S. Patterson, and S. Wyllie Nitro drugs for the treatment of trypanosomatid diseases: past, present, and future prospects Trends Parasitol 30 6 2014 289 298 Elsevier Ltd
93. B.S. Hall, C. Bot, and S.R. Wilkinson Nifurtimox activation by trypanosomal type I nitroreductases generates cytotoxic nitrile metabolites J Biol Chem 286 15 2011 13088 13095
94. E. Torreele, B. Bourdin Trunz, D. Tweats, M. Kaiser, R. Brun, and G. Mazué Fexinidazole - a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness PLoS Negl Trop Dis 4 12 2010 e923
95. M.T. Bahia, I.M. de Andrade, T.A.F. Martins, Á.F.D.S. do Nascimento, L.D.F. Diniz, and I.S. Caldas Fexinidazole: a potential new drug candidate for Chagas disease PLoS Negl Trop Dis 6 11 2012 e1870
96. M.T. Bahia, A.F.S. Nascimento, A.L. Mazzeti, L.F. Marques, K.R. Gonçalves, and L.W.R. Mota Antitrypanosomal activity of fexinidazole metabolites, potential new drug candidates for Chagas disease Antimicrob Agents Chemother 58 8 2014 4362 4370
97. M.V. Papadopoulou, B.B. Trunz, W.D. Bloomer, C. Mckenzie, S.R. Wilkinson, and C. Prasittichai Novel 3-nitro-1H-1,2,4-triazole-based aliphatic and aromatic amines as anti-Chagasic agents J Med Chem 54 2011 8214 8223
98. M.V. Papadopoulou, W.D. Bloomer, H.S. Rosenzweig, M. Kaiser, E. Chatelain, and J.-R. Ioset Novel 3-nitro-1H-1,2,4-triazole-based piperazines and 2-amino-1,3-benzothiazoles as antichagasic agents Bioorg Med Chem 21 21 2013 6600 6607 Elsevier Ltd
99. M.V. Papadopoulou, W.D. Bloomer, H.S. Rosenzweig, E. Chatelain, M. Kaiser, and S.R. Wilkinson Novel 3-nitro-1H-1,2,4-triazole-based amides and sulfonamides as potential antitrypanosomal agents J Med Chem 55 2012 5554 5565
100. M.V. Papadopoulou, W.D. Bloomer, H.S. Rosenzweig, R. Ashworth, M. Kaiser, and G. Andriani Novel 3-nitro-1H-1,2,4-triazole-based compounds as potential anti-Chagasic drugs: in vivo studies Future Med Chem 5 15 2013 1763 1776
101. C. Davies, R. Marino Cardozo, O. Sánchez Negrette, M.C. Mora, M.C. Chung, and M.A. Basombrío Hydroxymethylnitrofurazone is active in a murine model of Chagas' disease Antimicrob Agents Chemother 54 9 2010 3584 3589
102. E.O.P. Serafim, A.T.D.A.E. Silva, A.D.H. Moreno, E.D.O. Vizioli, E.I. Ferreira, and R.G. Peccinini Pharmacokinetics of hydroxymethylnitrofurazone, a promising new prodrug for Chagas' disease treatment Antimicrob Agents Chemother 57 12 2013 6106 6109
103. A.R. Germain, L.C. Carmody, C. Dockendorff, C. Galan-Rodriguez, A. Rodriguez, and S. Johnston Identification of small-molecule inhibitors of Trypansoma cruzi replication Bioorg Med Chem Lett 21 23 2011 7197 7200 Elsevier Ltd
104. G. Andriani, A.-D.C. Chessler, G. Courtemanche, B.A. Burleigh, and A. Rodriguez Activity in vivo of anti-Trypanosoma cruzi compounds selected from a high throughput screening PLoS Negl Trop Dis 5 8 2011 e1298
105. W. Apt, X. Aguilera, A. Arribada, C. Pérez, C. Miranda, and G. Sánchez Treatment of chronic Chagas' disease with itraconazole and allopurinol Am J Trop Med Hyg 59 1 1998 133 138
106. M.J.D.O. Toledo, M.T. Bahia, C.M. Carneiro, O.A. Martins-Filho, M. Tibayrenc, and C. Barnabé Chemotherapy with benznidazole and itraconazole for mice infected with different Trypanosoma cruzi clonal genotypes Antimicrob Agents Chemother 47 1 2003 223 230
107. S. Oh, S. Kim, S. Kong, G. Yang, N. Lee, and D. Han Synthesis and biological evaluation of 2,3-dihydroimidazo[1,2-a]benzimidazole derivatives against Leishmania donovani and Trypanosoma cruzi Eur J Med Chem 84 2014 395 403 Elsevier Masson SAS
108. F. Olmo, C. Rotger, I. Ramírez-Macías, L. Martínez, C. Marín, and L. Carreras Synthesis and biological evaluation of N, N'-squaramides with high in vivo efficacy and low toxicity: toward a low-cost drug against Chagas disease J Med Chem 57 3 2014 987 999
109. R.T. Jacobs, B. Nare, Sa. Wring, M.D. Orr, D. Chen, and J.M. Sligar SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis PLoS Negl Trop Dis 5 6 2011 e1151
110. M.N.C. Soeiro, and S.L. de Castro Trypanosoma cruzi targets for new chemotherapeutic approaches Expert Opin Ther Targets 13 1 2009 105 121
111. G. Rivera, V. Bocanegra-Garcia, C. Ordaz-Pichardo, B. Nogueda-Torres, and A. Monge New therapeutic targets for drug design against Trypanosoma cruzi, advances and perspectives Curr Med Chem 16 25 2009 3286 3293
112. W. Apt Current and developing therapeutic agents in the treatment of Chagas disease Drug Des Devel Ther 243 2010
113. V.G. Duschak, and A.S. Couto An insight on targets and patented drugs for chemotherapy of Chagas disease Recent Pat Antiinfect Drug Discov 2 2007 19 51
114. A. Cavalli, and M.L. Bolognesi Neglected tropical diseases: multi-target-directed ligands in the search for novel lead candidates against Trypanosoma and Leishmania J Med Chem 52 23 2009 7339 7359
115. M. Sajid, S.A. Robertson, L.S. Brinen, and J.H. Mckerrow The path from target validation to the clinic © 2011 Copyright Landes Bioscience. Not for Distribution 2011 100 115 [chapter 7]
116. M. Ndao, C. Beaulieu, W.C. Black, E. Isabel, F. Vasquez-Camargo, and M. Nath-Chowdhury Reversible cysteine protease inhibitors show promise for a Chagas disease cure Antimicrob Agents Chemother 58 2 2014 1167 1178
117. J.M. Dos Santos Filho, D.R.M. Moreira, C.A. de Simone, R.S. Ferreira, J.H. McKerrow, and C.S. Meira Optimization of anti-Trypanosoma cruzi oxadiazoles leads to identification of compounds with efficacy in infected mice Bioorg Med Chem 20 21 2012 6423 6433
118. J.M. Dos Santos Filho, A.C.L. Leite, B.G. de Oliveira, D.R.M. Moreira, M.S. Lima, and M.B.P. Soares Design, synthesis and cruzain docking of 3-(4-substituted-aryl)-1,2,4-oxadiazole-N-acylhydrazones as anti-Trypanosoma cruzi agents Bioorg Med Chem 17 18 2009 6682 6691 Elsevier Ltd
119. D.C. Greenbaum, Z. Mackey, E. Hansell, P. Doyle, J. Gut, and C.R. Caffrey Synthesis and structure-activity relationships of parasiticidal thiosemicarbazone cysteine protease inhibitors against Plasmodium falciparum, Trypanosoma brucei, and Trypanosoma cruzi J Med Chem 47 12 2004 3212 3219
120. N. Fujii, J.P. Mallari, E.J. Hansell, Z. Mackey, P. Doyle, and Y.M. Zhou Discovery of potent thiosemicarbazone inhibitors of rhodesain and cruzain Bioorg Med Chem Lett 15 1 2005 121 123
121. A.C.L. Leite, R.S. de Lima, D.R.D.M. Moreira, M.V.D.O. Cardoso, A.C. Gouveia de Brito, and L.M. Farias Dos Santos Synthesis, docking, and in vitro activity of thiosemicarbazones, aminoacyl-thiosemicarbazides and acyl-thiazolidones against Trypanosoma cruzi Bioorg Med Chem 14 11 2006 3749 3757
122. Sa. Carvalho, L.O. Feitosa, M. Soares, T.E.M.M. Costa, M.G. Henriques, and K. Salomão Design and synthesis of new (E)-cinnamic N-acylhydrazones as potent antitrypanosomal agents Eur J Med Chem 54 2012 512 521
123. M.M. Rabello, G. Bezerra, D.O. Filho, C. Moutinho, L. De Melo, and L. Ferreira Structural investigation of anti-Trypanosoma cruzi 2-iminothiazolidin-4-ones allows the identification of agents with efficacy in infected mice J Med Chem 55 2012 10918 10936
124. G. Colotti, P. Baiocco, A. Fiorillo, A. Boffi, E. Poser, and F. Di Chiaro Structural insights into the enzymes of the trypanothione pathway: targets for antileishmaniasis drugs Future Med Chem 5 15 2013 1861 1875
125. L.S.C. Bernardes, C.L. Zani, and I. Carvalho Trypanosomatidae diseases: from the current therapy to the efficacious role of trypanothione reductase in drug discovery Curr Med Chem 20 21 2013 2673 2696
126. G.A. DosReis Evasion of immune responses by Trypanosoma cruzi, the etiological agent of Chagas disease Braz J Med Biol Res 44 2011 84 90
127. L.O. Andrade, and N.W. Andrews The Trypanosoma cruzi-host-cell interplay: location, invasion, retention Nat Rev Microbiol 3 2005 819 823
128. P.T.V. Florentino, F. Real, A. Bonfim-Melo, C.M. Orikaza, E.R. Ferreira, and C.C. Pessoa An historical perspective on how advances in microscopic imaging contributed to understanding the Leishmania Spp. and Trypanosoma cruzi host-parasite relationship Biomed Res Int 2014 2014 10.1155/2014/565291 Arti:16 p
129. K.L. Caradonna, J.C. Engel, D. Jacobi, C.-H. Lee, and B.A. Burleigh Host metabolism regulates intracellualr growth of Trypanosoma cruzi Cell Host Microbe 13 2013 108 117
130. M.C. Fernandes, M. Cortez, A.R. Flannery, C. Tam, R.A. Mortara, and N.W. Andrews Trypanosoma cruzi subverts the sphingomyelinase-mediated plasma membrane repair pathway for cell invasion J Exp Med 208 5 2011 909 921
131. E.S. Barrias, U. de Carvalho, M. Tecia, and W. De Souza Trypanosoma cruzi: entry into mammalian host cells and parasitophorous vacuole formation Front Immunol 4 186 2013
132. L. Osorio, I. Ríos, B. Gutiérrez, and J. González Virulence factors of Trypanosoma cruzi: who is who? Microbes Infect 14 15 2012 1390 1402
133. S.S.C. Dc-Rubin, and S. Schenkman Trypanosoma cruzi trans-sialidase as a multifunctional enzyme in Chagas' disease Cell Microbiol 14 10 2012 1522 1530
134. A. Buschiazzo, M.F. Amaya, M.L. Cremona, A.C. Frasch, and P.M. Alzari The crystal structure and mode of action of trans-sialidase, a key enzyme in Trypanosoma cruzi pathogenesis Mol Cell 10 4 2002 757 768
135. M.F. Amaya, A.G. Watts, I. Damager, A. Wehenkel, T. Nguyen, and A. Buschiazzo Structural insights into the catalytic mechanism of Trypanosoma cruzi trans-sialidase Structure 12 5 2004 775 784
136. B.R. Miller III, and A.E. Roitberg Trypanosoma cruzi trans-sialidase as a drug target against Chagas disease (American trypanosomiasis) Future Med Chem 15 5 2013 1889 1900
137. W. Zheng Sirtuins as emerging anti-parasitic targets Eur J Med Chem 59 2013 132 140 Elsevier Masson SAS
138. J.J. Tanner, L. Boechi, J. Andrew McCammon, and P. Sobrado Structure, mechanism, and dynamics of UDP-galactopyranose mutase Arch Biochem Biophys 544 2014 128 141 Elsevier Inc
139. M. Oppenheimer, A.L. Valenciano, K. Kizjakina, J. Qi, and P. Sobrado Chemical mechanism of UDP-galactopyranose mutase from Trypanosoma cruzi: a potential drug target against Chagas' disease PLoS One 7 3 2012 e32918
140. E. Rodríguez, N. Lander, and J.L. Ramirez Molecular and biochemical characterisation of Trypanosoma cruzi phosphofructokinase Mem Inst Oswaldo Cruz 104 5 2009 745 748
141. K.R. Brimacombe, M.J. Walsh, L. Liu, H.P. Morgan, I. Mcnae, and L.A. Fothergill-gilmore Identification of ML251, a potent inhibitor of T. brucei and T. cruzi phosphofructokinase ACS Med Chem Lett 2014 8 13
142. C. Zhao, and S. Ma Recent advances in the discovery of N-myristoyltransferase inhibitors ChemMedChem 14 2014 1 14
143. S. Brand, L.a.T. Cleghorn, S.P. McElroy, D.a. Robinson, V.C. Smith, and I. Hallyburton Discovery of a novel class of orally active trypanocidal N-myristoyltransferase inhibitors J Med Chem 55 1 2012 140 152
144. A.J. Roberts, L.S. Torrie, S. Wyllie, and A.H. Fairlamb Biochemical and genetic characterization of Trypanosoma cruzi N-myristoyltransferase Biochem J 459 2 2014 323 332
145. G.C. Rodrigues, D.F. Feijó, M.T. Bozza, P. Pan, D. Vullo, and S. Parkkila Design, synthesis, and evaluation of hydroxamic acid derivatives as promising agents for the management of Chagas disease J Med Chem 57 2 2014 298 308
146. P. Pan, A.B. Vermelho, G. Capaci Rodrigues, A. Scozzafava, M.E.E. Tolvanen, and S. Parkkila Cloning, characterization, and sulfonamide and thiol inhibition studies of an α-carbonic anhydrase from Trypanosoma cruzi, the causative agent of Chagas disease J Med Chem 56 4 2013 1761 1771
147. Ö. Güzel-Akdemir, A. Akdemir, P. Pan, A.B. Vermelho, S. Parkkila, and A. Scozzafava A class of sulfonamides with strong inhibitory action against the α-carbonic anhydrase from Trypanosoma cruzi J Med Chem 56 14 2013 5773 5781
148. C. Fytas, G. Zoidis, N. Tzoutzas, M.C. Taylor, G. Fytas, and J.M. Kelly Novel lipophilic acetohydroxamic acid derivatives based on conformationally constrained spiro carbocyclic 2,6-diketopiperazine scaffolds with potent trypanocidal activity J Med Chem 54 14 2011 5250 5254
149. G. Benaim, J.M. Sanders, Y. Garcia-Marchán, C. Colina, R. Lira, and A.R. Caldera Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole J Med Chem 49 3 2006 892 899
150. D. Adesse, E.M. Azzam, M.D.N.L. Meirelles, J.A. Urbina, and L.R. Garzoni Amiodarone inhibits Trypanosoma cruzi infection and promotes cardiac cell recovery with gap junction and cytoskeleton reassembly in vitro Antimicrob Agents Chemother 55 1 2011 203 210
151. G. Benaim, V. Hernandez-Rodriguez, S. Mujica-Gonzalez, L. Plaza-Rojas, M.L. Silva, and N. Parra-Gimenez In vitro anti-Trypanosoma cruzi activity of dronedarone, a novel amiodarone derivative with an improved safety profile Antimicrob Agents Chemother 56 7 2012 3720 3725
152. G. Benaim, P. Casanova, V. Hernandez-Rodriguez, S. Mujica-Gonzalez, N. Parra-Gimenez, and L. Plaza-Rojas Dronedarone, an amiodarone analog with improved anti-Leishmania mexicana efficacy Antimicrob Agents Chemother 58 4 2014 2295 2303
153. D.J. Hammond, B. Cover, and W.E. Gutteridge A novel series of chemical structures active in vitro against the trypomastigote form of Trypanosoma cruzi Trans R Soc Trop Med Hyg 78 1 1984 91 95
154. T.J. Benson, J.H. McKie, J. Garforth, a. Borges, a.H. Fairlamb, and K.T. Douglas Rationally designed selective inhibitors of trypanothione reductase. Phenothiazines and related tricyclics as lead structures Biochem J 286 1992 9 11
155. H.W. Rivarola, J.M. Bustamante, S. Lo Presti, a.R. Fernández, J.E. Enders, and S. Gea Trypanosoma cruzi: chemotherapeutic effects of clomipramine in mice infected with an isolate obtained from an endemic area Exp Parasitol 111 2 2005 80 86
156. R. Fauro, S. Lo Presti, C. Bazan, A. Baez, M. Strauss, and F. Triquell Use of clomipramine as chemotherapy of the chronic phase of Chagas disease Parasitology 140 7 2013 917 927
157. A. Molina-Berríos, C. Campos-Estrada, N. Henriquez, M. Faúndez, G. Torres, and C. Castillo Protective role of acetylsalicylic acid in experimental Trypanosoma cruzi infection: evidence of a 15-epi-lipoxin A4-mediated effect PLoS Negl Trop Dis 7 4 2013 e2173
158. J.D. Planer, M.A. Hulverson, J.A. Arif, R.M. Ranade, R. Don, and F.S. Buckner Synergy testing of FDA-approved drugs identifies potent drug combinations against Trypanosoma cruzi PLoS Negl Trop Dis 8 7 2014 e2977
159. M. Witschel, M. Rottmann, M. Kaiser, and R. Brun Agrochemicals against malaria, sleeping sickness, leishmaniasis and Chagas disease PLoS Negl Trop Dis 6 10 2012 e1805